- Home
- DTIL vs YI Comparison
DTIL vs YI Comparison
Compare DTIL & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | YI |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8M | 60.2M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DTIL | YI |
|---|---|---|
| Price | $5.62 | $6.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | ★ 180.7K | 20.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $2.48 |
| 52 Week High | $8.82 | $11.35 |
Technical Indicators
Market Signals| Indicator | DTIL | YI |
|---|---|---|
| Relative Strength Index (RSI) | 73.04 | 41.42 |
| Support Level | $4.50 | $6.23 |
| Resistance Level | $5.80 | $6.86 |
| Average True Range (ATR) | 0.36 | 0.32 |
| MACD | 0.16 | -0.28 |
| Stochastic Oscillator | 79.86 | 23.46 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.